Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels.
We attempt to demonstrate the association between neuroleptic-induced hyperprolactinemia and sexual dysfunction in schizophrenic patients treated with prolactin-elevating antipsychotics. Our findings indicate that sexual function improved with euprolactinemia in patients switched from treatment with prolactin-elevating antipsychotics to olanzapine.
Ahl
Jonna
J
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 4133, Indianapolis, IN 46285, USA.
Kinon
Bruce J
BJ
Liu-Seifert
Hong
H
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D004542:Ejaculation / Q000187:drug effects; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood* / Q000139:chemically induced*; D008297:Male; D000077152:Olanzapine; D011388:Prolactin / Q000097:blood*; D011618:Psychotic Disorders / Q000150:complications / Q000188:drug therapy; D018967:Risperidone / Q000009:adverse effects / Q000627:therapeutic use; D012727:Sex Characteristics; D012735:Sexual Dysfunction, Physiological / Q000097:blood* / Q000139:chemically induced*; D020018:Sexual Dysfunctions, Psychological / Q000139:chemically induced / Q000523:psychology
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D011388:Prolactin; D018967:Risperidone; D000077152:Olanzapine